Latest News and Press Releases
Want to stay updated on the latest news?
-
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, May 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
-
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, May 09, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
-
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, April 24, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
-
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. Laval, QUEBEC, April 23, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
-
Important progress made with FDA on CaPre® development pathwayAmended IND application to commence bioavailability bridging study submittedEntered into licensing agreement with Neptune to market...
-
Supports Neptune in financing transaction by granting limited recourse pledge in the amount of $2.0M CDNEntered into positive operational arrangements with Neptune, including a licensing...
-
Encouraging response from FDA on CaPre® clinical developmentSeeking formal approval to commence bioavailability bridging study LAVAL, Quebec, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc....
-
LAVAL, Québec, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
-
Important progress made in FDA discussions on development pathway for CaPre® Reverse Stock Split effective October 15, 2015 LAVAL, Quebec, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Acasti...
-
LAVAL, Quebec, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...